https://investorplace.com/2021/01/7-equity-crowdfunding-offerings-to-buy-this-week-current/
Beverly Jedynak2021-01-28T15:37:17+00:00Phoenix offering included at InvestorPlace
Phoenix PharmaLabs Announces new Offering with Netcapital
Beverly Jedynak2021-01-19T17:59:33+00:00Full Article
Phoenix PharmaLabs Strengthens its Position as a Developer of Next Generation Pain Pharmaceuticals with Acquisition of a Portfolio of NOP/Mu Agonist Compounds
Beverly Jedynak2021-01-08T16:51:46+00:00Full Article
Lilly Joins the Push for Non-Opioid Painkillers
PPLadmin2020-12-10T19:32:22+00:00In Pharma Lilly joins the push for non-opioid painkillers 03-Jun-2019 By Maggie Lynch Eli Lilly acquires exclusive worldwide rights for non-opioid treatment for chronic pain from Centrexion through a licensing agreement. HTTPS://WWW.IN-PHARMATECHNOLOGIST.COM/ARTICLE/2019/06/03/ELI-LILLY-LICENSES-NON-OPIOID-TREATMENT-FOR-47.5M
Phoenix PharmaLabs Celebrates Successful Netcapital Equity Offering for Non-Addictive Opioid Pain Treatment
PPLadmin2020-12-10T19:33:52+00:00Crowdfund Insider Global Banking & Finance Review Biospace
Pain Medicine is Evolving – A Non-Addictive Opioid?
PPLadmin2020-12-10T19:38:27+00:00A non-addictive opioid under development by Phoenix PharmaLabs (Utah), PPL-103, has demonstrated the potential to be a treatment for opioid, as well as cocaine, addictions, as published in a poster by Lawrence Toll, PhD, professor of biomedical science at the Charles E. Schmidt College of Medicine at Florida Atlantic University, and chief neuropharmacologist of Phoenix [...]
How to fight drug addiction: the shift to prescription drugs
PPLadmin2020-12-10T19:42:00+00:00Full Article
In Vitro and In Vivo Profile of PPL-101 and PPL-103: Mixed Opioid Partial Agonist Analgesics with Low Abuse Potential
PPLadmin2020-12-10T19:45:37+00:00Full Article
One Stepfather’s Quest: The Search For An Opioid That Won’t Lead To Addiction
PPLadmin2020-12-10T19:50:44+00:00Full Article